Valuation: Oscotec Inc.

Capitalization 1,042B 755M 658M 618M 562M 1.04B 65.55B 1.17B 7.29B 2.82B 29.86B 2.83B 2.77B 110B P/E ratio 2025 *
78.3x
P/E ratio 2026 * 9.83x
Enterprise value 944M 684K 596K 560K 509K 939K 59.39M 1.06M 6.61M 2.55M 27.05M 2.57M 2.51M 99.65M EV / Sales 2025 *
16.6x
EV / Sales 2026 * 5.76x
Free-Float
87.14%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
Oscotec Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 05-14 CI
Oscotec Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 03-19 CI
Oscotec Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 11-13 CI
Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease 23/02/24 CI
Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease 14/09/23 CI
Oscotec Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 12/05/23 CI
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib 24/02/23 CI
Oscotec Inc. announced that it has received KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management 31/03/22 CI
Oscotec Inc. announced that it expects to receive KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management 23/03/22 CI
Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer Drug 02/03/21 CI
Oscotec Inc. announced that it has received KRW 21.9999934 billion in funding from E&Investment,Inc. 25/12/19 CI
Oscotec Inc. announced that it expects to receive KRW 21.9999934 billion in funding from E&Investment,Inc. 17/12/19 CI
Oscotec Inc. announced that it has received KRW 19.9999584 billion in funding from E&INVESTMENT INC., Samsung Securities Co. Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, AJU IB INVESTMENT Co., Ltd. 10/09/18 CI
More news
1 day-0.37%
1 week-1.62%
Current month-7.63%
1 month+2.83%
3 months-13.90%
6 months+8.78%
Current year+11.91%
More quotes
1 week 26,550
Extreme 26550
29,150
1 month 25,850
Extreme 25850
30,200
Current year 23,950
Extreme 23950
33,850
1 year 21,600
Extreme 21600
45,850
3 years 15,850
Extreme 15850
45,850
5 years 15,850
Extreme 15850
71,500
10 years 4,000
Extreme 4000
71,500
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 25/03/2020
Chief Executive Officer 65 19/04/2011
Corporate Officer/Principal 52 31/08/1999
Director TitleAgeSince
Director/Board Member 65 19/04/2011
Director/Board Member 52 31/08/1999
Director/Board Member 62 25/03/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.37%-1.62%-17.92%+10.10% 763M
-0.68%-6.44%-33.49%-30.91% 54.94B
-0.48%+0.06%-6.45%-12.19% 9.02B
+0.02%-1.36%+5.67%+20.34% 6.55B
-2.51%-5.69%+33.73%+104.89% 5.63B
-0.88%-3.22%+17.30%+29.60% 5.2B
-1.51%-12.26%+50.50%-0.98% 3.3B
+1.96%-0.57%+23.63%+21.98% 2.06B
-1.04%-4.73%-3.50%+15.95% 1.97B
-1.86%-5.37%-60.19%-11.63% 1.77B
Average -0.72%-3.15%+0.93%+14.72% 9.12B
Weighted average by Cap. -0.61%-4.20%-16.36%-9.54%
See all sector performances

Financials

2025 *2026 *
Net sales 57B 41.27M 35.99M 33.81M 30.75M 56.69M 3.58B 63.95M 399M 154M 1.63B 155M 152M 6.02B 148B 107M 93.13M 87.49M 79.56M 147M 9.28B 165M 1.03B 399M 4.23B 401M 392M 15.57B
Net income 13B 9.41M 8.21M 7.71M 7.01M 12.93M 818M 14.59M 90.97M 35.12M 372M 35.32M 34.57M 1.37B 106B 76.75M 66.93M 62.87M 57.18M 105M 6.67B 119M 742M 286M 3.04B 288M 282M 11.19B
Net Debt -98B -70.96M -61.88M -58.13M -52.86M -97.47M -6.16B -110M -686M -265M -2.81B -266M -261M -10.34B -192B -139M -121M -114M -104M -191M -12.08B -215M -1.34B -519M -5.5B -522M -511M -20.26B
More financial data * Estimated data
Logo Oscotec Inc.
Oscotec Inc.,Ltd is a Korea-based company mainly engaged in the manufacture of functional medical materials and related products. The Company operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The Company distributes its products within domestic market and to overseas markets.
Employees
51
More about the company
Date Price Change Volume
18/06/25 27,250.00 -0.37% 139,738
18/06/25 27,350.00 -0.18% 86,475
17/06/25 27,400.00 -1.08% 104,504
16/06/25 27,700.00 -1.25% 246,269
13/06/25 28,050.00 -0.71% 176,386

End-of-day quote Korea S.E., June 18, 2025

More quotes
Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
27,250.00KRW
Average target price
56,000.00KRW
Spread / Average Target
+105.50%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A039200 Stock